Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Ireland

Research and Innovation Action · Running

RESTORE VISION Novel advanced and repurposed therapeutics for vision restoration in a group of severe rare ocular surface diseases: from validation to first clinical investigations

Coordinator
University of Galway, Ireland
Runs
1 May 2023 to 30 April 2027
Status
Running
EU funding
€8.0m
Total cost
€8.0m
Partners
10 organisations in 9 countries
Type
Research and Innovation Action
Grant agreement
101080611

What the project is doing

In the project's own words, from its summary on CORDIS.

Rare Eye Diseases (REDs) are a major cause of visual impairment and blindness in Europe, affecting patients of all ages. The RESTORE VISION Consortium identified a group of 7 REDs all affecting the cornea and ocular surface that cause severe vision impairment and blindness and have inadequate treatment options today. Onset and progression is characterised by overlapping common pathophysiologic mechanisms: defective corneal wound healing, nerve degeneration, stem-cell dysfunction and aberrant vessel ingrowth.

The 7 REDs targeted are Aniridia-Associated Keratopathy, Neurotrophic Keratopathy, Limbal Stem Cell Deficiency, Ocular Cicatricial Pemphigoid, EEC Syndrome, Ocular Graft versus Host Disease and Corneal Neovascularisation, affecting over 500k patients in Europe. Current management is often prohibitively expensive, has low efficacy and leads to debilitating side effects, pointing to a critical medical problem and area of unmet medical need.

RESTORE VISION brings together actors from across the full value chain: 6 leading research institutions, 3 SMEs and a European patient organisation. We take a ground-breaking approach to improve eye health by verifying disease pathomechanisms, using cutting-edge models for each rare disease to test novel and repurposed compounds and determine drug mechanisms of action, formulating compounds as safe eye drop suspensions or subconjunctival drugs, and performing several first-in-human trials of novel therapies.

New therapeutics with game-changing potential will be evaluated for the first time. Our pioneering ‘streams’ approach is based on the repurposing of 6 existing drugs and the development of 3 new compounds, all with solid preliminary data showing remarkable effects in restoring the cell physiology, immune, avascular, neural and signalling environment in the cornea. This innovative approach shortcircuits lengthy and complex regulatory and drug development processes, ensuring rapid translation into the clinic.

Topics

Who is involved

OrganisationCityCountryRole
University of GalwayGalwayIrelandCoordinator
Klinikum Der Universitaet Zu KoelnKoelnGermanyParticipant
Cell2cure ApsBirkerodDenmarkParticipant
Universidad Miguel Hernandez De ElcheElcheSpainParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Laboratoires KolClermont FerrandFranceParticipant
Ospedale San Raffaele SRLMilanoItalyParticipant
Catalyze B.V.Amsterdam-DuivendrechtNetherlandsParticipant
Aniridia EuropeSandefjordNorwayParticipant
Linkopings UniversitetLinkopingSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI